OS Therapies (OSTX) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed OS Therapies (OSTX) over the past year, gaining 208.4% versus a loss of 53.0%. Rallybio is the larger company by market cap ($43.3 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | RLYB |
|---|---|---|
| Share price | $0.803 | $15.47 |
| Market cap | $42.00M | $43.32M |
| 1-day change | -2.12% | -0.32% |
| YTD return | -42.64% | +181.89% |
| 1-year return | -53.04% | +208.41% |
| 5-year return | — | -85.29% |
| P/E ratio (TTM) | — | 3.36 |
| Forward P/E | 2.29 | — |
| EPS (TTM) | $-1.08 | $4.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | $-28.75M | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $2.25 | $35.15 |
| 52-week low | $0.58 | $7.34 |
| Distance from 52-week high | -64.31% | -55.99% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +958.53% | — |
| Average volume | 722.66K | 10.14K |
| Shares outstanding | 52.30M | 2.80M |
| Employees | 4 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed OSTX by 261.5 percentage points over the past year.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
OSTX vs RLYB FAQ
Which is bigger, OS Therapies or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $42.00M for OS Therapies (OSTX).
Which stock has performed better over the past year, OSTX or RLYB?
RLYB returned +208.41% over the past 12 months, compared with -53.04% for OSTX (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.